CA2009326C - Aqueous granulation solution and a method of tablet granulation - Google Patents
Aqueous granulation solution and a method of tablet granulationInfo
- Publication number
- CA2009326C CA2009326C CA002009326A CA2009326A CA2009326C CA 2009326 C CA2009326 C CA 2009326C CA 002009326 A CA002009326 A CA 002009326A CA 2009326 A CA2009326 A CA 2009326A CA 2009326 C CA2009326 C CA 2009326C
- Authority
- CA
- Canada
- Prior art keywords
- potassium
- sodium
- granulate
- bicarbonate
- granulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an aqueous granulating solution containing sodium, potassium or mixed sodium potassium salt of an edible organic acid chosen from the group consisting of citric, malic, tartaric or fumaric acid and optionally containing sodium or potassium bicarbonate. The granulating solution is especially useful for granulating finely divided solids including acetaminophen, ketoprofen or calcium carbonate. The resulting granulate may be used to prepare a swallow tablet or mixed with an edible organic acid and the mixture tableted to provide an effervescent tablet without resorting to controlled reaction or special handling techniques.
Description
~v ~
AN AQUEOUS GRANULATION SOLUTION
AND A METHOD OF TABLET GRANULATION
Field of the Invention The invention relates to the use of alkali metal salts of edible organic acids as granulating agents in aqueous solution, granulates of finely divided solids made using such solutions and a me~hod of wet granulation using these granulating solutions. The granulating solutions and method are useful for the production of pharmaceutical tablets and granulations, particularly effervescent tablets.
Background of the Invention Wet granulation techniques have been used for many years by the pharmaceutical industry. Tradi-tional granulating agents such as starch, gelatin,sucrose, acacia, hydroxypropylmethylcellulose and polyvinylpyrrolidone have been used to provide a freely flowing granulation mixture, tabletability, aqueous solubility or dispersibility of the medically effective ingredient, and so forth. Alkali metal salts of edible organic acids such as trisodium citrate, tripotassium citrate, dipotassium fumarate and sodium potassium tartrate have not been used as granulating agents previously. Trisodium citrate has MS #1582 2~Q~32&
been used in powder form as a stabilizer ~or dichlora-phenazone (GB 882567) which mixture is then granulated to form tablets for pharmaceutical use.
Special problems have been found with the granulation and tableting of effervescent compositions because the compounds required for the effervescent couple react during granulation. Methods have been developed which involve the controlled reaction of the effervescent couple to produce a dry granulation mixture of the couple. This mixture must be carefully handled in a humidity controlled environment. The medically effective ingredient, often an analgesic, is granulated sep~rately and the two granulation mixtures combined for tableting. Sodium bicarbonate, a commonly used reactant in effervescent mixtures, is not wet granulated as such or in mixtures, in the preparation of stable effervescent systems, except in carefully controlled reaction systems ContA; n; ny the acidic components of the effervescent couple and using very small amounts of water or water-solvent mixtures. ~ven then, the granulation is sometimes aided by heat to liberate water from the sodium bicarbonate by decomposition. Sodium citrate may be formed as the reaction product between the components of effervescent couples such as sodium bicarbonate and citric acid when granulated together. However, special precautions, by drying or controlling the reaction, have been required.
It has now been found that by using an aqueous solution containing an effective amount of an ~lk~l i metal salt of an edible organic acid as a granulating agent, traaitional wet gr~nulating techniques may be MS #1582 used. These granulating agents allow all of the nonacid components of the desired final formulation to be granulated together without special handling techniques.
Summary of the Invention The invention discloses a method of preparing a granulate of a finely divided solid material, by mixing an effective amount of an aqueous granulatinq solution of a potassium or sodium or mixed sodium potassium salt of an edible organic acid chosen from the group consisting of citric acid, malic acid, fumaric acid and tartraic acid, which granulating solution may optionally also contain sodium or potassium bicarbonate, with a finely divided solid material requiring granulation; granulating the mixture and drying the granulated mixture.
Medically effective ingredients such as aceta-minophen, calcium carbonate, ketoprofen or sodium or potassium bicarbonate may be granulated by this method. The dried granulate is then mixed with an edible organic acid to form an effervescent powder which may be tableted into conventional effervescent tablets; or as appropriate, the dried granulate may be mixed with other tableting excipients and made into swallow tablets.
Description of the Invention It has been found that aqueous so]utions of potassium or sodium or mixed sodium potassium salt of 2:~
an cdible organic acid chosen from the group consisting of citric acid, rnalic acid, fumaric acid and tartaric acid may be used as granulating agents. Trisodium citrate, tripotassium citrate, dipotassium Eumarate and sodium potassium tartrate are particularly preferred for use with bicarbonates and nonacid ingredients which will be tableted with reactive ingredients such as organic acids.
Usage of this wet granulation method with trisodium citrate has allowed for the successful large scale manufacturing of an effervesc~nt tablet containing, among other things, potassium bicarbonate and fumaric acid. Severe production problems, based on the spontaneous reaction of potassium bicarbonate and fumaric acid were found when these ingredients were simply dry mixed together. Use of an aqueous granulated form of potassium bicarbonate protected with a granulating agent of this invention eliminated this problem.
As used herein, the phrase "aqueous granulating solution" refers to a solution of the alkali metal salt which may optionally contain sodium cr potassium bicarbonate. The term "granulate" refers to the dried mixture granulated with the addition of the aqueous granulating solution. To form a final formulation or tablet, the granulate may be mixed with other ingredients or used as is.
An aqueous granulating solution of trisodium citrate or of trisodium citrate and potassium bicar-bonate is especially useful for granulating mixturesof metallic salts of bicarbonate and carbonate and other formula ingredients for multicomponent MS #1582 -5~
effervescent mixtures. The trisodium citrate granulate mixture is mixed and tableted with an edible organic acid such as citricr malic, fumaric acid, and the like, to produce an effervescent tablet. 5uch mixtures then show high dissolution reactivity rates as well as good binding characteristics for tahleting, good free flowing properties, good dispersal properties for contained insoluble paxticles such as aspirin and acetaminophen and high reactivity xates for insoluble o carbonates lik~ calcium carbonate.
In effervescent formulations, a bicarbonate and an organic acid are used as the effervescent couple.
Traditionally the bicarbonate has been either sodium or potassium bicarbonate and the organic acid has been citric acid. The organic acid may, however, also be fumaric, tartaric, malic or succinic acid or any one of a number of edible organic acids. When potassium bicarbonate and fumaric acid are used together, without prior protec~ive treatment, the two ingredients react spontaneously, creating a problem in the traditional tableting procedures. In solving this problem, it was found that trisodium citrate, tripotassium citrate, dipotassium fumarate, and/or sodium potassium tartrate could be granulated onto potassium bicarbonate and any other nonacid components of the formulation in need of granulation by tradi-tional wet granulation methods. The organic acid could then be mixed with the dried nonacid granulation and tableted. This means that it is no longer necessary to use controlled reaction methods of preparing the effervescent couple granulation.
Production of effervcscent tablets, or powders, is MS #1582 -6~
therefore substantially simplified. This simpllfi-cation leads to lncreased convenience and decrea6ed cost of manufacture.
The nonacid components which may be included in the trisodium citrate, tripotassium citrate, dipotas-sium fumarate, or sodium potassium tartrate wet granulation are varied, but it is particularly convenient to add pharmaceutically active ingredients which require granulation. Such ingredients include calcium carbonate and analgesics, especially acetamin-ophen, which is difficult to granulate. Although the granulate is primarily applicable to nonacid components, slightly acidic compon~nts can be tolerated, for example ketoprofen. The phrase "nonacid components"
is generally intended to exclude the major acidic ingredient which would make up the acid component of the effervescent couple. These "nonacid" ingredients may be included alone or in combination with potassium and/or sodium bicarbonate. The formulation may of course be an antacid where potassium and/or sodium bicarbonate may be used as the pharmaceutically active ingredient. Other nonacid ingredients may also be included, such as flavors, bulkin~ agents and the like.
The aqueous granulating solution is commonly a saturated solution of the alkali metal salt at ambient temperature to provide for ease of preparation and convenience. For example, for trisodium citrate this is about 40% w/w; for dipotassium fumarate, this is about 20% w/w; and for sodium potassium tartrate, this is about 40% w/w. When the sodium or potassium bicarbonate i5 added to the aqueous granulating MS #1582 -7~
solution the proportion will be, for exampl~, trisodium citrate ~0~ w/w and potassium bicarbonate 10% w/w.
The concentrations given herein are based on the usc of water as a solvent. Variation of these concentra~
tions is well within the skill of those versed in the art given the guidance found herein. Of course lower concentrations would be possible if longer drying times or higher drying temperatures were considered acceptable. It is preferred that the pH of the aqueous granulating solution be about neutral, or about pH 7 or above, especially when the granulate contains a bicarbonate and will be used to prepare an effervescent couple; in order to avoid reaction with the bicarbonate. Therefore, essentially neutralized salts, such as trisodium citrate, tripotassium citrate, dipotassium fumarate and sodium potassium tartrate are preferred.
The following examples disclose preferred embodiments of the invention, but do not limit the applicability of the invention which is solely defined by the claims.
EXAMPLES
In the following examples, the granulating solution refers to an aqueous solution containing 2s sodium, potassium or mixed sodium potassium salt or an edible organic acid such as citric, malic, tartaric or fumaric acid and optionally sodium or potassium bicarbonate. Sodium citrate is used as a synonym for trisodium citrate. The formulas shown for the granulate include the concentration of ~lk~li metal MS #1582 ,~ ~3 salt, and optionally bicarbonate, contributed by the aqueous granulating solution and r~m~i n; ng in the mixture when the granulate is dried. The general procedure is to load the finely divided solid material requiring granulation together into a Patterson-Kelley V-Blender, with an intensifier bar. The blender used for experimental purposes had a capacity of eigh~
guarts. The blender is then run, with the intensifier bar on, while the granulating solution is added; and the run is continued for an additional time of about four minutes. The amount of time the hlender is run is approximate and can readily be determined by one of ordinary skill in the art for various formulations.
The granulate is then discharged from the blender and spread onto a tray to dry overnight, or about 16 hours, in a forced hot air oven at 60~ C. The time, temperature or equipment used in drying is not critical as long as it is sufficient to dry the granulate without causing decomposition of the components. For example, a fluid bed dryer may be used in place of a forced air oven. The general procedure outlined above is used in the examples unless otherwlse specified.
Example 1 - Preparation of a trisodium citrate granulate of potassium bicarbonate, G-6.
A granulate of potassium bicarbonate was prepared using an aqueous solution of trisodium citrate as the granulating agent. This granulate may be mixed with other formula ingredients, lncluding fumaric acid, and tableted without special h~n~l; ng techniques to ~S #1582 2 ~
g produce an effervescent antacid tablet. When potas-sium bicarbonate is not so protected during granula-tion, the blcarbonate will react spon-taneously with fumaric acid.
Granulating Solution % w/w Ingredient Wt.
40.0 Sodium Citrate, Dihydrate8.0 kg 60.0 D.I. Water 12.0 kg 100.0 20.0 kg Granulate, G-6 % w/w Ingredient Wt.
95.8 Potassium Bicarbonate, U.S.P. 136 kg 4.2 Sodium Citrate 6 kg 100.0 142 kg The granulating solution is prepared by dissolving the sodium citrate in the D.I. Water with stirring.
The granulate, G-6, is prepared in a Littleford-Lodige MixerlGranulator of nine cubic foot total capacity.
Potassium bicarbonate (300 lbs.) is loaded into the mixer. The mixer is run for three minutes with the choppers turned on, in order to break up any lumps in the material. A total of 15.0 kg of granulating solution is added to the mixer while it is running, with the choppers on. The mixer is run for eleven minutes, until a suitable granulate is formed. The MS #1582 Z i~ 9 granulate is discharged from the mixer and dried at 82~C.
The comparative dry state reactivity of micronized fumaric acid with potassium bicarbonate versus its reactivity with G-6 was studied by mixing 10 Gm of each and placing in a closed container with a moisture ~rap in the vent. The container was held at room temperature ~24~C) and weighed at selected intervals.
When dried but untreated potassium bicarbonate was used, there was a weight loss due to evolution of carbon dioxide, which proceeded rapidly at a rate of about 2 Gm/hour, to near 70% completion, at which time there was an abrupt change to a rate of about O.002 Gm/hour. When G-6 granulate of Example 1 was used in place of dried, but untreated, potassium bicarbonate, there was no perceptible reaction over 143 hours.
Example 2 - Preparation of a trisodium citrate and potassium bicarbonate granulate of sodium bicarbonate, G-80.
A granulate of sodium bicarbonate was prepared using an aqueous solution of trisodium citrate and potassium bicarbonate as the granulating agent. This granulate was useful for the preparation of efferves-cent aspirin tablets.
MS #1582 Granulating Solution w/w Ingredient Wt.
20.0 Sodium Citrate Dihydrate400 Gm 10.0 Potassium ~icarbonate, U.S.P. 200 Gm 570.0 D.I. Water 1400 Gm 100.0 2000 Gm Granulate, G-80 % w/w Ingredient Wt.
97.9 Sodium Bicarbonate, U.S.P.*7000 Gm 101.4 Sodium Citrate 100 Gm 0.7 Potassium Bicarbonate 50 Gm 100.0 7150 Gm *Church and Dwight Co., Inc.; #2 Fine Granular The granulating solution is prepared by dissolving the sodium citrate and the potassium bicarbonate in the D.I. Water with stirring. The granulate, G-80, is prepared as described in the general procedure above. The sodi~ bicarbonate is loaded into the blender. A total of 500 Gm of granulating solution is added to the blender. The blender is run for an additional four minutes after the granulating solution has ~een added. The resulting granulate is discharged from the mixer and dried.
The granulate, G-80, composed primarily of bicarbonate was used to prepare an effervescent analgesic preparation cont~i ni ng aspirin.
MS #1582 ~3~ .,$
Formula ET-17~
mg/tab Ingredient Wt.
325 Aspirin, U.S.P. 162.5 Gm 1000 Citric Acid, Anhydrous Powder 500.0 Gm 51957 G-80 978.5 Gm 3282 1641.0 Gm The G-80 granulate was dry sized by passage through a 2B S.S. drilled screen on a Model M Fitz-patrick Comminuting Mill, operating at 25~0 rpm, knives forward. Together the citric acid and aspirin are passed through a ~24 S.S. Screen, U.S. Standard.
This mixture and the G-80 granulate are loaded into a tabletop Patterson-Kelley Twin Shell Blender, and mixed for eight minutes. The final mixture is compressed into tablets of one inch diameter to a tablet hardness of 9-12 kilopounds (kp).
The resulting ta~lets dissolve rapidly (within approximately one minute) when placed in water. The dissolved tablet solution has good esthetic properties;
the aspirin crystals on the surface are easily dispersed into the solution ~y swirling, without leaving an unsightly scum ring on the sides of the glass, and the solution has a prolonged residual effervescence.
MS #1582 Example 3 - Preparation of a trisodium citrate granulate of a mixture of potassium bicarbonate and acetaminophen.
An aqueous granulating solution of trisodium citrate was used to produce a granulate composed of potassium bicarbonate and acetaminophen.
Granulating Solution % w/w ~ngredient Wt.
40.0 Sodium Citrate, Dihydrate8.0 kg 1060.0 D.I. Water 12.0 kg 100.0 20.0 kg Granulate, G-73 % w/w Ingredient Wt.
45.6 Potassium Bicarbonate, U.S.P. 2100.0 Gm 1549.5 Acetaminophen, U.S.P.2275.0 Gm 4.9 Sodium Citrate 224.5 Gm 100.0 4599.5 Gm The granulate is prepar~d as descri~d in the general procedure. Potassium bicarbonate and acet-aminophen are loaded into the blender and are drymixed for four minutes. A total of 600 Gm of granu-lating solution is added to the blender while lt is running. The blender is then run for a total of 15 minutes. The granulate is discharged from the mixer and dried at 71~C.
MS #1582 E~ample ~ - Preparation of a trisodium citrate granulate of a mixture o~ potassium bicarbonate acetaminophen and calcium carbonate.
Acetaminophen and calcium carbonate are both finely divided solids which are difficult to granu-late and tabletO It was found that an aqueous solution of trisodium citrate could be successfully used to prepare a granulate containing these ingre-dients and potassium bicarbonate. This granulate may be used to prepare an effervescent tablet without special ~n~l i ng techniques.
Granulating Solution % w/w In~redient Wt.
40.0 Sodium Citrate, Dihydrate8.0 kg 1560.0 D~I. Water 12.0 kg 100.0 ~0.0 kg Granulate, G-74 % w/w Ingredient Wt.
28.6 Precipitated Calcium Carbonate, 1255.5 Gm ~.S.P.
30.8 Potassium Bicarbonate, U.S.P. 1350.0 Gm 33.3 Acetaminophen~ U.S.P.1462.5 Gm 7.3 Sodium Citrate 320.0 Gm 100.0 4388.0 Gm MS #1582 --15 ~ ~ ~ ~r The granulatc, G-74, is prepared as described in the general procedure. Calcium car~onate, potassium bicarbonate and acetaminophen are loaded in-to the blender and are dry mixed for four minutes. A total of 800 Gm of granulating solution is added to the blender while it is running. The blender is run for four minutes after the solution has been added~ The gran~late is discharged from the mixer and dried at 71~C.
Example 5 ~ Preparation of a trisodium citrate granulate of a mixture of sodium bicarbonatc, calcium carbonate, potassium bicarbonate and acetaminophen.
In order to show that amount of solids which may be granulated may vary, as may the amount of bicar-bonate, another granulate was prepared with anagueous trisodium citrate granulating solution.
Granulating Solution % w/w Ingredicnt Wt.
_ 40.0 Sodium Citrate, Dihydrate8.0 kg 2060.0 D.I. Water 12.0 kg 100.0 20.0 MS #1582 ~P~fi Granulate, G-76 w/w Ingredient Wt.
32.5 Sodium Bicarbonate, u.S.P.*1662.5 Gm 19.1 Precipitated Calcium Carbonate USP 376.5 Gm 520.6 Potassium Bicarbonate/ U.S.P.1050.0 Gm 22.3 Acetaminophen, U.S.P. 1137.5 Gm 5.5 Sodium Citrate 280.0 Gm 100.0 5106.5 Gm *Church and Dwight Co., Inc.; #5 Coarse Granular The granulate, G-76, is prepared as described in the general procedure. Sodium bicarbonate, calcium carbonate, potassium bicarbonate and acetaminophen are loaded into the blender and dry mixed for four minutes. A total of 700 Gm of granulating solution is added to the blender while it is running. The blender is run for five minutes after the solution has been added. The granulate is discharged from the mixer and dried.
The granulate, G-76, cont~ining acetaminophen is used to prepare an effervescent analgesic ta~let.
MS #1582 -17~ e~s~
Formula ET-185 mg~tab Ingredient Wt.
1459 G-76 437.7 Gm 887 Citric Acid, Anhydrous Powder 266.1 Gm 5553 DiPac, Sugar 165.9 Gm Fumaric Acid, Micronized24.0 Gm 1 Polyvinylpyrrolidone, K29-320.3 Gm 2980 894.0 Gm The G-76 granulate was dry sized by passage through a 0.033 inch opening, drilled S.S. screen at 3550 rpm, on a Model JT Homoloid Machine of the W. J.
Fitzpatrick Co. Citric acid, DiPac sugar and fumaric acid were passed through a #16 S.S. Screen, U.S.
Standard. This mixture, the G-76 granulate and the polyvinylpyrrolidone are loaded into a jar, closed with a lid, and mixed for seven minutes on a Turbula Type T10~ Mixer. The final mixture is compressed into ~ablets of one inch diameter to a tablet hardness of 6-8 Kp.
The resulting tablets dissolve rapidly ~within approximately one minute and 20 seconds) when placed in wa~er. The dissolved tablet solution has good esthetic properties; there is no surface scum of insoluble materials to deal with~ the solution has only a slight turbidity to it (which clears upon standing), and the solution has a prolonged residual effervescence.
MS #1582 Example 6 - Preparation of a trisodiurn citrate granulate of acetaminophen.
An aqueous solution of trisodium citrate may be used ~s a granulating agent without the addition of a bicar~onate.
Granulating Solution % w/w Ingredient Wt.
40.0 Sodium Citrate, Dihydrate 8.0 kg 60.0 D.I. Water 12.0 kg 10100.0 20.0 kg Granulate, G-77 % w/w Ingredient Wt.
89.8 Acetaminophen 3500 Gm 10.2 Sodium Citrate 400 Gm 15100.0 3900 Gm The granulate, G-77, is prepared as described in the general procedure. Acetaminophen is loaded into the blender. A total of 1000 Gm of granulating solution is added to the blender while it is running.
The blender is run Eor five minutes after the solution has been added. The granulate is discharged from the mixer and dried.
MS #1582 Example 7 - Preparation of a -trisodium citrate granulate o~ a mix-ture of ketoprofen, sodi~ bicar-bonate, calcium carbonate and potassium bicarbonate.
An aqueous solution of trisodium citrate was successfully used to granulate a mixture composed of bicarbonates, calcium carbonate and a slightly acidic analgesic, ketoprofen. The resulting granulate may be used to prepare an effervescent sachet.
Granulating Solution lO % w/w Ingredient Wt.
40.0 Sodium Citrate, Dihydrate 8.0 kg 60.0 D.I. Water 12~0 kg 100.0 20.0 kg Granulate, G-78 15 % w/w Ingredient Wt.
2.2 Ketoprofen** 112.5 Gm 41.8 Sodium Bicarbonate, U.S.P.* 2137.5 Gm 24.5 Precipitated Calcium Carbonate, 1255.5 Gm U.SOP.
26.4Potassium Bicarbonate, U.S.P. 1350.0 Gm 5.1 Sodium Citrate260.0 Gm 100.0 5115.5 Gm *Church and Dwigh~ Co., Inc.; #5 Coarse Granular ** Ketoprofen is an acidic compound. However, the resultant granulate is not acidic.
MS #1582 -20- ~ 3~
The granulate, G-78, is prepared as described in the general procedure. Ketoprofen, sodium bicarbonate, calcium carbonate and potassium bicar-bonate are loaded into the blender and are dr~ mixed 5 for four minutes. A total of 650 Gm of granulating solution is added to the blender while it is running.
The blender is run for six minutes after the solution has been added. The granulate is discharged from the mixer and dried.
This run indicates the ability of granulates to accomrnodate minor arnounts of stable acidic ingredientsO
G-78 contains 2.2% of ketoprofen, a proprionic acid derivative. Granulation of this small arnount of an acidic drug within the bicarbonate-carbonate mixture is easily accomplished using trisodium citrate wet granulation methodology. G-78 granulate is useful for the formulation and prepara~ion of sachet dosage forms of ketoprofen, without the fear of ketoprofen active ingredient segregation despite its low concentration within the bulk of the formu-lation dosage.
Example 8 - Preparation of a trisodium citrate and potassium bicarbonate granulate of a mixture of potassium bicarbonate, calcium carbonate and sodium bicarbonate.
An aqueous solution of trisodiurn citrate and potassium bicarbonate may be used to granulate bicarbonates and calcium carbonate.
MS #1S~2 2B0932~
Granulating Solution ~n W/W Ingredient Wt.
Sodium Citrate, Dihydrate 240 Gm Potassium Bicarbonate, U.S.P. 120 Gm 5 70 D.I. Water 840 Gm 100 1200 Gm Granulate, G~79 % w/w Ingredient Wt.
33.0 Potassium Bicarbonate, U.S.P. 1S60 Gm**
lo26.4 Precipitated Calcium Carbonate, 1250 Gm U.S.P.
38.1 Sodium Bicarbonate, U.S.P.*1800 Gm 2.5 Sodium Citrate 120 Gm 100.0 4730 Gm *Church and Dwight Co., Inc.; #2 Fine Granular **Includes 60 Gm from Granulating Solution The granulate, G-79, is prepared as described in the general procedure. Potassium bicarbonate, calcium carbonate and sodium bicarbonate are loaded into the blender and are dry mixed for four minutes.
A total of ~00 Gm of granulating solution is added to the blender while it is running. The blender is run for six minutes after the solution has been added.
The granulate is discharged from the mixer and dried.
MS #1582 2 ~
Example ~ - Preparation of a trisodium citrate and potassium bicarbonate granulate of a mixture of acctaminophen, potassiurn bicarbonate, sodium bicar-bonate and calcium carbonate.
Granulating Solution % w/w Ingredient Wt.
Sodium Citrate, Dihydrate400 Gm Potassium Bicarbonate, U.S.P. 200 Gm D.I. Water 1400 Gm 10100 2000 Gm Granulate, G-81 % w/w Ingredient Wt.
27.6 Acetaminophen, U.S.P.1100 Gm 21.0 Potassium Bicarbonate, U.S.P. 935 Grn**
1526.2 Sodium Bicarbonate, U.S.P.* 1100 Gm 22.6 Precipitated Calcium Carbonate, 946 Gm U.S.P.
2.6 Sodium Citrate 110 Cm 100.0 4191 Gm *Church and Dwight Co., Inc.; #2 Fine Granular **Includes 55 ~m from Granulating Solution The granulate, G-81, is prepared as described in the general procedure. Acetaminophen, potassium bicarbonate, sodium bicarbonate and calcium carbonate MS #1582 are loaded into the blender and are dry mixed for seven minutes. A total of 550 Gm of granulating solution is added to the blender while it is running.
The blender is run for six minutes after the solution has been added. The granulate is discharged from the mixer and dried.
G-81 was dry sized through a 0.033 inch opening, drilled S.S. screen at 3550 rpm on a Model JT Homoloid Machine, as it would be for use in a tablet formula-tion, where material flowability is of importance. Aflow test was run by placing 1000 Gm of the sized granulate into a 0.5 inch bottom opening tablet pr2ss hopper, set above a recording balance. The granulate was found to flow freely, as required for good manufacturing capability, at approximately 1233 Gm/minute through the hopper opening.
Example 10 - Preparation of a tripotassium citrate granulate of sodium bicarbonate, G-10.
An aqueous solution of tripotassium citrate may also be used as a granulating agent for bicarbonate and will also protect the bicarbonate from reaction with the acid component of a effervescent couple.
Granulating Solution ~ w/w Ingredient Wt.
2550 Potassium Citrate, Tribasic 1000 Gm D.I. Water 1000 Gm 100 2000 Gm MS #1582 -24- ~ 3~:~
This solutlon is made by reacting citric acid and potassium bicarbonate as follows:
Ingredient Wt.
Citric Acid, Anhydrous 627 Gm Potassium Bicarbonate 980 Gm D.I. Water 824 Gm The citric acid is dissolved in the water, held in an oversized container. Potassium bicarhonate is added slowly with good mixing while effervescence of the solution proceeds. The effervescent reaction is endothermic so that the solution becomes very cold.
The solution is warmed gently back up to about room temperature before it is used.
Granulate, G-10 15 % w/w Ingredient Wt.
96.0 Sodium Bicarbonate, U.S.P.* 4.8 Kg 4.0 Potassium Citrate 0.2 Kg 100.0 5.0 Kg *Church and Dwight Co., Inc., #2 The granulate is prepared as described in the general procedure. Sodium bicarbonate is loaded into the blender. It is attrited by running for five minutes with the intensifier bar on. A total of 400 Gm of granulating solution is added to the blender MS #1582 ~2~- 2~Q~3~
while it is running. The blender is then run for a total of 5iX minutes af~cr the solution addition.
The granulate ls discharged from the mixer and dried.
The G-10 granulate may be used to prepare an effervescent aspirin tahlet formulation.
Formula ET-187 mg/tab Ingredient Wt.
325 Aspirin, U.S.P. 162.5 Gm 1000 Citric Acid, Anhydrous Powder 500.0 Gm 102160 G-10 1080~0 ~m 3485 1742.5 Gm The G-10 granulate was dry sized by passage through a 2B S.S. drilled screen on a Model M Fitz-patrick Comminuting Mill, operating at 2500 rpm, knives forward. Together the citric acid and aspirin are passed through a #24 S.Sc Screen, U.S. Standard~
This mixture and the G-10 granulate are loaded into a tabletop Patterson-Kelley Twin Shell Blender, and mixed for seven minutes. The final mixture is compressed into tablets of one inch diameter to a tablet hardness of 9-12 Kp.
The resulting tablets dissolve rapidly (within approximately one minute) when placed in water. The dissolved tablet solution has good esthetic properties;
the aspirin crystals on the surface are easily dispersed into the solution by swirling, without leaving an unsightly scum ring on the sides of the glass, and the solution has a prolonged residual effervescence.
MS #1582 2~3~
Example 11 Aspirin containing effervescent tablets made with sodium bicarbonate granulates prepared with different aqueous granulating solutions for comparison.
Aqueous solutions of sodium citrate ~ET-179, Example 2)~ potassium citrate (ET-187, Example 10) and dibasic potassium fumarate (ET-339, Example 15) were compared with a similar formulation, made with heat treated sodium bicarbonate, as a control. The tablets were packaged into foil pouches cont~ining two tablets each of the respective formulations, and were tested for stability after 1 week storage at 40~C. Formulations ET-179, ET-187 and ET-339 were used as disclosed and are nonoptimized laboratory formulations. The control is a commercial, optimized product. The tablets were tested for aspirin decomposition, which was followed by the genera~ion of sodium salicylate, and for carbon dioxide genera-tion, which was followed by measurement of the physical expansion of the pouch packages. The following results were obtained:
1 Week 40~C
Sodium Salicylate Pouch Expansion Formulation mg/tab mm/pouch 25 ET-179 6.35 12.7 ET-187 5.35 3-7 ET-339 5.42 1.7 Control 5.50 0.9 MS ~1582 It can be seen from these data that ET-179, ET-187 and ET--339 are approximately equivalent to the control formulation in the matter of sodium salicylate generation as an indicator of aspirin decomposition, but not as resistant to carbon dioxide liberation from the formulations as is the control formulation.
However, all three formulations were within acceptable limits, especially for nonoptimized formulations, and were much easier to manufacture since normal wet granulation techniques could be used and special handling was not re~uired.
Example 12 - Preparation of a trisodium citrate granulate of a mixture of acetaminophen and calcium carbonate, G-1.
Two particularly troublesome compounds to granulate are acetaminophen and calcium carbonate.
Granulating Solution % w/w Ingredient Wt.
40.0 Sodium Citra~e, Dihydrate 600 Gm 20 60.0 D.I. Water _ Gm 100.0 1500 Gm MS #1582 3i~
Granulate, G-1 % w/w Ingredient Wt.
42.0 Acetaminophen, U.S.P.1772.5 Gm 49.0 Precipitated Calcium Carbonate, 2072.5 Gm U.S.P.
9.0 Sodium Citrate 380.0 Gm 100.0 4225.0 Gm The granulate, G-1, was prepared using the general procedure described previously and used to prepare a swallow tahlet.
Formula T-48 mg/tab Ingredient Wt.
782.82 G-1 626.26 Gm 31.79 Sodium Starch Glycolate, N.F. 25.43 Gm (Explotab) 0.10 Docusate: Sodium Benzoate (85:15) 0.08 Gm 4.00 Magnesium Stearate, N.F.3.20 Gm 10.00 Crospovidone, N.F. (Polyplasdone 8.00 Gm XL) 2048.29 Powdered Cellulose, N.F. (Keycel 38.63 Gm BH65) 9.00 Colloidal Silicon Dioxide, N.F. 7.20 Gm (Syloid 244FP) 886.00 708.80 Gm MS #1582 32~
The G l granulate was dry sized by passage tnrough a 0.033 inch opening, drilled S.S. screen at 3550 rpm, on a Model JT Homoloid Machine from the W.
J. Fitzpatrick Co. All ingredients except the magnesium stearate were passed through a ~24 U.S.
Standard S.S. screen two times, and then mixed in a two quart capacity V-Blender for five minutes. The magnesium stearate was delumped by spatulation and then added to the V-Blender, and the whole composition was mixed for three minutes. The composition was compressed into tablets using 0~300" x 0.700" x 0.050" (cup depth) capsule shaped tooling on a Colton 216 tablet press.
The resulting tablets had a cross sectional breaking strength of 4.6 Kp, and showed U.S.P.
dissolution test results of 94~0% at 30 minutes for acetaminophen and 99.9% at 30 minutes for calcium.
Example 13 - Preparation of a dipotassium fumarate granulate of potassium bicarhonate, G-83.
Granulating Solution O w/w Ingredient Wt.
19.2 Potassium Fumarate, Dibasic 1000 Gm 80.8 D.I. Water 4200 Gm 100.0 5200 Gm MS #1582 30~
This solu~ion is made by reacting fumaric acid and potassium bicarbonate as follows:
Ingredi.ent Wt.
Fumaric Acid, N.F.601 Gm Potassium Bicarbonate, U.S.P. 1036 Gm D.I. Water 4014 Gm The potassium bicarbonate was dissolved in the water, the fumaric acid added slowly with mixing while effervescence of the solution proceeds. The solution is warmed gently to about 44~C before it is used.
Granulate G-83 % w/w Ingredient Wt.
97.4 Potassium Bicarbonate, U.S.P. 5000 Gm 2.6 Potassium Fumarate, Dibasic 135 Gm 100.0 5135 Gm The G-83 granulate was prepared as described in the general procedure outlined previously.
MS #1582 2~93,~
Example 14 - Prcparation of a potassium sodium tartrate granulate of potassium bicarbonate, G-85.
Granulating Solution % w/w Ingredicnt Wt.
40.0 Potassium Sodium Tartrate, U.S.P. 500 Gm 60.0 D~I. Water 750 Gm 100.0 1250 Gm - Granulate, G-85 % w/w Ingredient Wt.
94.7 Potassium Bicarbonate, U.S.P. 5000 Gm 5.3 Potassium Sodium Tartrate, U.S.P. 280 Gm 100.0 5280 Gm The G-85 granulate was prepared as described in the general procedure outlined previously.
Tes~ of dry state reactivity of micronized fumaric acid with dipotassium fumarate granulate of potassium bicarbonate, ~-83, and with potassium sodium tartrate granulate of potassium bicarbonate, G-85.
Testing was conducted according to Example 12.
There was no perceptible reaction of G-83 or G-85 with micronized fumaric acid over 45 hours.
MS #1582 2~ i3~
Example 15 - Preparation of a dipotassium fumarate granulate of sodium bicarbonate, G-84.
The granulating solution of dipotassium Eumarate described in Example 13 was used to prepare granulate G-84. The granulate was prepared as described in the general procedure outline previously.
Granulate G-84 % w/w Ingredient Wt.
97.75 Sodium Bicaxbonate, U.S.P.*5000 Gm 102.25 Potassium Fumarate, Dibasic115 Gm 100.00 5115 Gm The G-84 granulate was used to prepare an effervescent aspirin tablet formulation.
Formula ET-339 15 mg/tab Ingredient Wt.
1983 G-84 594.9 1000 Citric Acid, Anhydrous Powder 300.0 324 Aspirin, U.S.P. 97.2 3307 992.1 The procedure used to test the tablets has been outlined in Example 10. The results were generally the same as those shown in Example 10. A comparison of effervescent tablets made with this method is shown in Example 11.
MS #1582 3 ~ ~
It should be understood that many modifications and variations can be made i.n the proportions and components used hercin without departing from the spirit and scope of the invention, which is solely defined by the claims.
MS #1582
AN AQUEOUS GRANULATION SOLUTION
AND A METHOD OF TABLET GRANULATION
Field of the Invention The invention relates to the use of alkali metal salts of edible organic acids as granulating agents in aqueous solution, granulates of finely divided solids made using such solutions and a me~hod of wet granulation using these granulating solutions. The granulating solutions and method are useful for the production of pharmaceutical tablets and granulations, particularly effervescent tablets.
Background of the Invention Wet granulation techniques have been used for many years by the pharmaceutical industry. Tradi-tional granulating agents such as starch, gelatin,sucrose, acacia, hydroxypropylmethylcellulose and polyvinylpyrrolidone have been used to provide a freely flowing granulation mixture, tabletability, aqueous solubility or dispersibility of the medically effective ingredient, and so forth. Alkali metal salts of edible organic acids such as trisodium citrate, tripotassium citrate, dipotassium fumarate and sodium potassium tartrate have not been used as granulating agents previously. Trisodium citrate has MS #1582 2~Q~32&
been used in powder form as a stabilizer ~or dichlora-phenazone (GB 882567) which mixture is then granulated to form tablets for pharmaceutical use.
Special problems have been found with the granulation and tableting of effervescent compositions because the compounds required for the effervescent couple react during granulation. Methods have been developed which involve the controlled reaction of the effervescent couple to produce a dry granulation mixture of the couple. This mixture must be carefully handled in a humidity controlled environment. The medically effective ingredient, often an analgesic, is granulated sep~rately and the two granulation mixtures combined for tableting. Sodium bicarbonate, a commonly used reactant in effervescent mixtures, is not wet granulated as such or in mixtures, in the preparation of stable effervescent systems, except in carefully controlled reaction systems ContA; n; ny the acidic components of the effervescent couple and using very small amounts of water or water-solvent mixtures. ~ven then, the granulation is sometimes aided by heat to liberate water from the sodium bicarbonate by decomposition. Sodium citrate may be formed as the reaction product between the components of effervescent couples such as sodium bicarbonate and citric acid when granulated together. However, special precautions, by drying or controlling the reaction, have been required.
It has now been found that by using an aqueous solution containing an effective amount of an ~lk~l i metal salt of an edible organic acid as a granulating agent, traaitional wet gr~nulating techniques may be MS #1582 used. These granulating agents allow all of the nonacid components of the desired final formulation to be granulated together without special handling techniques.
Summary of the Invention The invention discloses a method of preparing a granulate of a finely divided solid material, by mixing an effective amount of an aqueous granulatinq solution of a potassium or sodium or mixed sodium potassium salt of an edible organic acid chosen from the group consisting of citric acid, malic acid, fumaric acid and tartraic acid, which granulating solution may optionally also contain sodium or potassium bicarbonate, with a finely divided solid material requiring granulation; granulating the mixture and drying the granulated mixture.
Medically effective ingredients such as aceta-minophen, calcium carbonate, ketoprofen or sodium or potassium bicarbonate may be granulated by this method. The dried granulate is then mixed with an edible organic acid to form an effervescent powder which may be tableted into conventional effervescent tablets; or as appropriate, the dried granulate may be mixed with other tableting excipients and made into swallow tablets.
Description of the Invention It has been found that aqueous so]utions of potassium or sodium or mixed sodium potassium salt of 2:~
an cdible organic acid chosen from the group consisting of citric acid, rnalic acid, fumaric acid and tartaric acid may be used as granulating agents. Trisodium citrate, tripotassium citrate, dipotassium Eumarate and sodium potassium tartrate are particularly preferred for use with bicarbonates and nonacid ingredients which will be tableted with reactive ingredients such as organic acids.
Usage of this wet granulation method with trisodium citrate has allowed for the successful large scale manufacturing of an effervesc~nt tablet containing, among other things, potassium bicarbonate and fumaric acid. Severe production problems, based on the spontaneous reaction of potassium bicarbonate and fumaric acid were found when these ingredients were simply dry mixed together. Use of an aqueous granulated form of potassium bicarbonate protected with a granulating agent of this invention eliminated this problem.
As used herein, the phrase "aqueous granulating solution" refers to a solution of the alkali metal salt which may optionally contain sodium cr potassium bicarbonate. The term "granulate" refers to the dried mixture granulated with the addition of the aqueous granulating solution. To form a final formulation or tablet, the granulate may be mixed with other ingredients or used as is.
An aqueous granulating solution of trisodium citrate or of trisodium citrate and potassium bicar-bonate is especially useful for granulating mixturesof metallic salts of bicarbonate and carbonate and other formula ingredients for multicomponent MS #1582 -5~
effervescent mixtures. The trisodium citrate granulate mixture is mixed and tableted with an edible organic acid such as citricr malic, fumaric acid, and the like, to produce an effervescent tablet. 5uch mixtures then show high dissolution reactivity rates as well as good binding characteristics for tahleting, good free flowing properties, good dispersal properties for contained insoluble paxticles such as aspirin and acetaminophen and high reactivity xates for insoluble o carbonates lik~ calcium carbonate.
In effervescent formulations, a bicarbonate and an organic acid are used as the effervescent couple.
Traditionally the bicarbonate has been either sodium or potassium bicarbonate and the organic acid has been citric acid. The organic acid may, however, also be fumaric, tartaric, malic or succinic acid or any one of a number of edible organic acids. When potassium bicarbonate and fumaric acid are used together, without prior protec~ive treatment, the two ingredients react spontaneously, creating a problem in the traditional tableting procedures. In solving this problem, it was found that trisodium citrate, tripotassium citrate, dipotassium fumarate, and/or sodium potassium tartrate could be granulated onto potassium bicarbonate and any other nonacid components of the formulation in need of granulation by tradi-tional wet granulation methods. The organic acid could then be mixed with the dried nonacid granulation and tableted. This means that it is no longer necessary to use controlled reaction methods of preparing the effervescent couple granulation.
Production of effervcscent tablets, or powders, is MS #1582 -6~
therefore substantially simplified. This simpllfi-cation leads to lncreased convenience and decrea6ed cost of manufacture.
The nonacid components which may be included in the trisodium citrate, tripotassium citrate, dipotas-sium fumarate, or sodium potassium tartrate wet granulation are varied, but it is particularly convenient to add pharmaceutically active ingredients which require granulation. Such ingredients include calcium carbonate and analgesics, especially acetamin-ophen, which is difficult to granulate. Although the granulate is primarily applicable to nonacid components, slightly acidic compon~nts can be tolerated, for example ketoprofen. The phrase "nonacid components"
is generally intended to exclude the major acidic ingredient which would make up the acid component of the effervescent couple. These "nonacid" ingredients may be included alone or in combination with potassium and/or sodium bicarbonate. The formulation may of course be an antacid where potassium and/or sodium bicarbonate may be used as the pharmaceutically active ingredient. Other nonacid ingredients may also be included, such as flavors, bulkin~ agents and the like.
The aqueous granulating solution is commonly a saturated solution of the alkali metal salt at ambient temperature to provide for ease of preparation and convenience. For example, for trisodium citrate this is about 40% w/w; for dipotassium fumarate, this is about 20% w/w; and for sodium potassium tartrate, this is about 40% w/w. When the sodium or potassium bicarbonate i5 added to the aqueous granulating MS #1582 -7~
solution the proportion will be, for exampl~, trisodium citrate ~0~ w/w and potassium bicarbonate 10% w/w.
The concentrations given herein are based on the usc of water as a solvent. Variation of these concentra~
tions is well within the skill of those versed in the art given the guidance found herein. Of course lower concentrations would be possible if longer drying times or higher drying temperatures were considered acceptable. It is preferred that the pH of the aqueous granulating solution be about neutral, or about pH 7 or above, especially when the granulate contains a bicarbonate and will be used to prepare an effervescent couple; in order to avoid reaction with the bicarbonate. Therefore, essentially neutralized salts, such as trisodium citrate, tripotassium citrate, dipotassium fumarate and sodium potassium tartrate are preferred.
The following examples disclose preferred embodiments of the invention, but do not limit the applicability of the invention which is solely defined by the claims.
EXAMPLES
In the following examples, the granulating solution refers to an aqueous solution containing 2s sodium, potassium or mixed sodium potassium salt or an edible organic acid such as citric, malic, tartaric or fumaric acid and optionally sodium or potassium bicarbonate. Sodium citrate is used as a synonym for trisodium citrate. The formulas shown for the granulate include the concentration of ~lk~li metal MS #1582 ,~ ~3 salt, and optionally bicarbonate, contributed by the aqueous granulating solution and r~m~i n; ng in the mixture when the granulate is dried. The general procedure is to load the finely divided solid material requiring granulation together into a Patterson-Kelley V-Blender, with an intensifier bar. The blender used for experimental purposes had a capacity of eigh~
guarts. The blender is then run, with the intensifier bar on, while the granulating solution is added; and the run is continued for an additional time of about four minutes. The amount of time the hlender is run is approximate and can readily be determined by one of ordinary skill in the art for various formulations.
The granulate is then discharged from the blender and spread onto a tray to dry overnight, or about 16 hours, in a forced hot air oven at 60~ C. The time, temperature or equipment used in drying is not critical as long as it is sufficient to dry the granulate without causing decomposition of the components. For example, a fluid bed dryer may be used in place of a forced air oven. The general procedure outlined above is used in the examples unless otherwlse specified.
Example 1 - Preparation of a trisodium citrate granulate of potassium bicarbonate, G-6.
A granulate of potassium bicarbonate was prepared using an aqueous solution of trisodium citrate as the granulating agent. This granulate may be mixed with other formula ingredients, lncluding fumaric acid, and tableted without special h~n~l; ng techniques to ~S #1582 2 ~
g produce an effervescent antacid tablet. When potas-sium bicarbonate is not so protected during granula-tion, the blcarbonate will react spon-taneously with fumaric acid.
Granulating Solution % w/w Ingredient Wt.
40.0 Sodium Citrate, Dihydrate8.0 kg 60.0 D.I. Water 12.0 kg 100.0 20.0 kg Granulate, G-6 % w/w Ingredient Wt.
95.8 Potassium Bicarbonate, U.S.P. 136 kg 4.2 Sodium Citrate 6 kg 100.0 142 kg The granulating solution is prepared by dissolving the sodium citrate in the D.I. Water with stirring.
The granulate, G-6, is prepared in a Littleford-Lodige MixerlGranulator of nine cubic foot total capacity.
Potassium bicarbonate (300 lbs.) is loaded into the mixer. The mixer is run for three minutes with the choppers turned on, in order to break up any lumps in the material. A total of 15.0 kg of granulating solution is added to the mixer while it is running, with the choppers on. The mixer is run for eleven minutes, until a suitable granulate is formed. The MS #1582 Z i~ 9 granulate is discharged from the mixer and dried at 82~C.
The comparative dry state reactivity of micronized fumaric acid with potassium bicarbonate versus its reactivity with G-6 was studied by mixing 10 Gm of each and placing in a closed container with a moisture ~rap in the vent. The container was held at room temperature ~24~C) and weighed at selected intervals.
When dried but untreated potassium bicarbonate was used, there was a weight loss due to evolution of carbon dioxide, which proceeded rapidly at a rate of about 2 Gm/hour, to near 70% completion, at which time there was an abrupt change to a rate of about O.002 Gm/hour. When G-6 granulate of Example 1 was used in place of dried, but untreated, potassium bicarbonate, there was no perceptible reaction over 143 hours.
Example 2 - Preparation of a trisodium citrate and potassium bicarbonate granulate of sodium bicarbonate, G-80.
A granulate of sodium bicarbonate was prepared using an aqueous solution of trisodium citrate and potassium bicarbonate as the granulating agent. This granulate was useful for the preparation of efferves-cent aspirin tablets.
MS #1582 Granulating Solution w/w Ingredient Wt.
20.0 Sodium Citrate Dihydrate400 Gm 10.0 Potassium ~icarbonate, U.S.P. 200 Gm 570.0 D.I. Water 1400 Gm 100.0 2000 Gm Granulate, G-80 % w/w Ingredient Wt.
97.9 Sodium Bicarbonate, U.S.P.*7000 Gm 101.4 Sodium Citrate 100 Gm 0.7 Potassium Bicarbonate 50 Gm 100.0 7150 Gm *Church and Dwight Co., Inc.; #2 Fine Granular The granulating solution is prepared by dissolving the sodium citrate and the potassium bicarbonate in the D.I. Water with stirring. The granulate, G-80, is prepared as described in the general procedure above. The sodi~ bicarbonate is loaded into the blender. A total of 500 Gm of granulating solution is added to the blender. The blender is run for an additional four minutes after the granulating solution has ~een added. The resulting granulate is discharged from the mixer and dried.
The granulate, G-80, composed primarily of bicarbonate was used to prepare an effervescent analgesic preparation cont~i ni ng aspirin.
MS #1582 ~3~ .,$
Formula ET-17~
mg/tab Ingredient Wt.
325 Aspirin, U.S.P. 162.5 Gm 1000 Citric Acid, Anhydrous Powder 500.0 Gm 51957 G-80 978.5 Gm 3282 1641.0 Gm The G-80 granulate was dry sized by passage through a 2B S.S. drilled screen on a Model M Fitz-patrick Comminuting Mill, operating at 25~0 rpm, knives forward. Together the citric acid and aspirin are passed through a ~24 S.S. Screen, U.S. Standard.
This mixture and the G-80 granulate are loaded into a tabletop Patterson-Kelley Twin Shell Blender, and mixed for eight minutes. The final mixture is compressed into tablets of one inch diameter to a tablet hardness of 9-12 kilopounds (kp).
The resulting ta~lets dissolve rapidly (within approximately one minute) when placed in water. The dissolved tablet solution has good esthetic properties;
the aspirin crystals on the surface are easily dispersed into the solution ~y swirling, without leaving an unsightly scum ring on the sides of the glass, and the solution has a prolonged residual effervescence.
MS #1582 Example 3 - Preparation of a trisodium citrate granulate of a mixture of potassium bicarbonate and acetaminophen.
An aqueous granulating solution of trisodium citrate was used to produce a granulate composed of potassium bicarbonate and acetaminophen.
Granulating Solution % w/w ~ngredient Wt.
40.0 Sodium Citrate, Dihydrate8.0 kg 1060.0 D.I. Water 12.0 kg 100.0 20.0 kg Granulate, G-73 % w/w Ingredient Wt.
45.6 Potassium Bicarbonate, U.S.P. 2100.0 Gm 1549.5 Acetaminophen, U.S.P.2275.0 Gm 4.9 Sodium Citrate 224.5 Gm 100.0 4599.5 Gm The granulate is prepar~d as descri~d in the general procedure. Potassium bicarbonate and acet-aminophen are loaded into the blender and are drymixed for four minutes. A total of 600 Gm of granu-lating solution is added to the blender while lt is running. The blender is then run for a total of 15 minutes. The granulate is discharged from the mixer and dried at 71~C.
MS #1582 E~ample ~ - Preparation of a trisodium citrate granulate of a mixture o~ potassium bicarbonate acetaminophen and calcium carbonate.
Acetaminophen and calcium carbonate are both finely divided solids which are difficult to granu-late and tabletO It was found that an aqueous solution of trisodium citrate could be successfully used to prepare a granulate containing these ingre-dients and potassium bicarbonate. This granulate may be used to prepare an effervescent tablet without special ~n~l i ng techniques.
Granulating Solution % w/w In~redient Wt.
40.0 Sodium Citrate, Dihydrate8.0 kg 1560.0 D~I. Water 12.0 kg 100.0 ~0.0 kg Granulate, G-74 % w/w Ingredient Wt.
28.6 Precipitated Calcium Carbonate, 1255.5 Gm ~.S.P.
30.8 Potassium Bicarbonate, U.S.P. 1350.0 Gm 33.3 Acetaminophen~ U.S.P.1462.5 Gm 7.3 Sodium Citrate 320.0 Gm 100.0 4388.0 Gm MS #1582 --15 ~ ~ ~ ~r The granulatc, G-74, is prepared as described in the general procedure. Calcium car~onate, potassium bicarbonate and acetaminophen are loaded in-to the blender and are dry mixed for four minutes. A total of 800 Gm of granulating solution is added to the blender while it is running. The blender is run for four minutes after the solution has been added~ The gran~late is discharged from the mixer and dried at 71~C.
Example 5 ~ Preparation of a trisodium citrate granulate of a mixture of sodium bicarbonatc, calcium carbonate, potassium bicarbonate and acetaminophen.
In order to show that amount of solids which may be granulated may vary, as may the amount of bicar-bonate, another granulate was prepared with anagueous trisodium citrate granulating solution.
Granulating Solution % w/w Ingredicnt Wt.
_ 40.0 Sodium Citrate, Dihydrate8.0 kg 2060.0 D.I. Water 12.0 kg 100.0 20.0 MS #1582 ~P~fi Granulate, G-76 w/w Ingredient Wt.
32.5 Sodium Bicarbonate, u.S.P.*1662.5 Gm 19.1 Precipitated Calcium Carbonate USP 376.5 Gm 520.6 Potassium Bicarbonate/ U.S.P.1050.0 Gm 22.3 Acetaminophen, U.S.P. 1137.5 Gm 5.5 Sodium Citrate 280.0 Gm 100.0 5106.5 Gm *Church and Dwight Co., Inc.; #5 Coarse Granular The granulate, G-76, is prepared as described in the general procedure. Sodium bicarbonate, calcium carbonate, potassium bicarbonate and acetaminophen are loaded into the blender and dry mixed for four minutes. A total of 700 Gm of granulating solution is added to the blender while it is running. The blender is run for five minutes after the solution has been added. The granulate is discharged from the mixer and dried.
The granulate, G-76, cont~ining acetaminophen is used to prepare an effervescent analgesic ta~let.
MS #1582 -17~ e~s~
Formula ET-185 mg~tab Ingredient Wt.
1459 G-76 437.7 Gm 887 Citric Acid, Anhydrous Powder 266.1 Gm 5553 DiPac, Sugar 165.9 Gm Fumaric Acid, Micronized24.0 Gm 1 Polyvinylpyrrolidone, K29-320.3 Gm 2980 894.0 Gm The G-76 granulate was dry sized by passage through a 0.033 inch opening, drilled S.S. screen at 3550 rpm, on a Model JT Homoloid Machine of the W. J.
Fitzpatrick Co. Citric acid, DiPac sugar and fumaric acid were passed through a #16 S.S. Screen, U.S.
Standard. This mixture, the G-76 granulate and the polyvinylpyrrolidone are loaded into a jar, closed with a lid, and mixed for seven minutes on a Turbula Type T10~ Mixer. The final mixture is compressed into ~ablets of one inch diameter to a tablet hardness of 6-8 Kp.
The resulting tablets dissolve rapidly ~within approximately one minute and 20 seconds) when placed in wa~er. The dissolved tablet solution has good esthetic properties; there is no surface scum of insoluble materials to deal with~ the solution has only a slight turbidity to it (which clears upon standing), and the solution has a prolonged residual effervescence.
MS #1582 Example 6 - Preparation of a trisodiurn citrate granulate of acetaminophen.
An aqueous solution of trisodium citrate may be used ~s a granulating agent without the addition of a bicar~onate.
Granulating Solution % w/w Ingredient Wt.
40.0 Sodium Citrate, Dihydrate 8.0 kg 60.0 D.I. Water 12.0 kg 10100.0 20.0 kg Granulate, G-77 % w/w Ingredient Wt.
89.8 Acetaminophen 3500 Gm 10.2 Sodium Citrate 400 Gm 15100.0 3900 Gm The granulate, G-77, is prepared as described in the general procedure. Acetaminophen is loaded into the blender. A total of 1000 Gm of granulating solution is added to the blender while it is running.
The blender is run Eor five minutes after the solution has been added. The granulate is discharged from the mixer and dried.
MS #1582 Example 7 - Preparation of a -trisodium citrate granulate o~ a mix-ture of ketoprofen, sodi~ bicar-bonate, calcium carbonate and potassium bicarbonate.
An aqueous solution of trisodium citrate was successfully used to granulate a mixture composed of bicarbonates, calcium carbonate and a slightly acidic analgesic, ketoprofen. The resulting granulate may be used to prepare an effervescent sachet.
Granulating Solution lO % w/w Ingredient Wt.
40.0 Sodium Citrate, Dihydrate 8.0 kg 60.0 D.I. Water 12~0 kg 100.0 20.0 kg Granulate, G-78 15 % w/w Ingredient Wt.
2.2 Ketoprofen** 112.5 Gm 41.8 Sodium Bicarbonate, U.S.P.* 2137.5 Gm 24.5 Precipitated Calcium Carbonate, 1255.5 Gm U.SOP.
26.4Potassium Bicarbonate, U.S.P. 1350.0 Gm 5.1 Sodium Citrate260.0 Gm 100.0 5115.5 Gm *Church and Dwigh~ Co., Inc.; #5 Coarse Granular ** Ketoprofen is an acidic compound. However, the resultant granulate is not acidic.
MS #1582 -20- ~ 3~
The granulate, G-78, is prepared as described in the general procedure. Ketoprofen, sodium bicarbonate, calcium carbonate and potassium bicar-bonate are loaded into the blender and are dr~ mixed 5 for four minutes. A total of 650 Gm of granulating solution is added to the blender while it is running.
The blender is run for six minutes after the solution has been added. The granulate is discharged from the mixer and dried.
This run indicates the ability of granulates to accomrnodate minor arnounts of stable acidic ingredientsO
G-78 contains 2.2% of ketoprofen, a proprionic acid derivative. Granulation of this small arnount of an acidic drug within the bicarbonate-carbonate mixture is easily accomplished using trisodium citrate wet granulation methodology. G-78 granulate is useful for the formulation and prepara~ion of sachet dosage forms of ketoprofen, without the fear of ketoprofen active ingredient segregation despite its low concentration within the bulk of the formu-lation dosage.
Example 8 - Preparation of a trisodium citrate and potassium bicarbonate granulate of a mixture of potassium bicarbonate, calcium carbonate and sodium bicarbonate.
An aqueous solution of trisodiurn citrate and potassium bicarbonate may be used to granulate bicarbonates and calcium carbonate.
MS #1S~2 2B0932~
Granulating Solution ~n W/W Ingredient Wt.
Sodium Citrate, Dihydrate 240 Gm Potassium Bicarbonate, U.S.P. 120 Gm 5 70 D.I. Water 840 Gm 100 1200 Gm Granulate, G~79 % w/w Ingredient Wt.
33.0 Potassium Bicarbonate, U.S.P. 1S60 Gm**
lo26.4 Precipitated Calcium Carbonate, 1250 Gm U.S.P.
38.1 Sodium Bicarbonate, U.S.P.*1800 Gm 2.5 Sodium Citrate 120 Gm 100.0 4730 Gm *Church and Dwight Co., Inc.; #2 Fine Granular **Includes 60 Gm from Granulating Solution The granulate, G-79, is prepared as described in the general procedure. Potassium bicarbonate, calcium carbonate and sodium bicarbonate are loaded into the blender and are dry mixed for four minutes.
A total of ~00 Gm of granulating solution is added to the blender while it is running. The blender is run for six minutes after the solution has been added.
The granulate is discharged from the mixer and dried.
MS #1582 2 ~
Example ~ - Preparation of a trisodium citrate and potassium bicarbonate granulate of a mixture of acctaminophen, potassiurn bicarbonate, sodium bicar-bonate and calcium carbonate.
Granulating Solution % w/w Ingredient Wt.
Sodium Citrate, Dihydrate400 Gm Potassium Bicarbonate, U.S.P. 200 Gm D.I. Water 1400 Gm 10100 2000 Gm Granulate, G-81 % w/w Ingredient Wt.
27.6 Acetaminophen, U.S.P.1100 Gm 21.0 Potassium Bicarbonate, U.S.P. 935 Grn**
1526.2 Sodium Bicarbonate, U.S.P.* 1100 Gm 22.6 Precipitated Calcium Carbonate, 946 Gm U.S.P.
2.6 Sodium Citrate 110 Cm 100.0 4191 Gm *Church and Dwight Co., Inc.; #2 Fine Granular **Includes 55 ~m from Granulating Solution The granulate, G-81, is prepared as described in the general procedure. Acetaminophen, potassium bicarbonate, sodium bicarbonate and calcium carbonate MS #1582 are loaded into the blender and are dry mixed for seven minutes. A total of 550 Gm of granulating solution is added to the blender while it is running.
The blender is run for six minutes after the solution has been added. The granulate is discharged from the mixer and dried.
G-81 was dry sized through a 0.033 inch opening, drilled S.S. screen at 3550 rpm on a Model JT Homoloid Machine, as it would be for use in a tablet formula-tion, where material flowability is of importance. Aflow test was run by placing 1000 Gm of the sized granulate into a 0.5 inch bottom opening tablet pr2ss hopper, set above a recording balance. The granulate was found to flow freely, as required for good manufacturing capability, at approximately 1233 Gm/minute through the hopper opening.
Example 10 - Preparation of a tripotassium citrate granulate of sodium bicarbonate, G-10.
An aqueous solution of tripotassium citrate may also be used as a granulating agent for bicarbonate and will also protect the bicarbonate from reaction with the acid component of a effervescent couple.
Granulating Solution ~ w/w Ingredient Wt.
2550 Potassium Citrate, Tribasic 1000 Gm D.I. Water 1000 Gm 100 2000 Gm MS #1582 -24- ~ 3~:~
This solutlon is made by reacting citric acid and potassium bicarbonate as follows:
Ingredient Wt.
Citric Acid, Anhydrous 627 Gm Potassium Bicarbonate 980 Gm D.I. Water 824 Gm The citric acid is dissolved in the water, held in an oversized container. Potassium bicarhonate is added slowly with good mixing while effervescence of the solution proceeds. The effervescent reaction is endothermic so that the solution becomes very cold.
The solution is warmed gently back up to about room temperature before it is used.
Granulate, G-10 15 % w/w Ingredient Wt.
96.0 Sodium Bicarbonate, U.S.P.* 4.8 Kg 4.0 Potassium Citrate 0.2 Kg 100.0 5.0 Kg *Church and Dwight Co., Inc., #2 The granulate is prepared as described in the general procedure. Sodium bicarbonate is loaded into the blender. It is attrited by running for five minutes with the intensifier bar on. A total of 400 Gm of granulating solution is added to the blender MS #1582 ~2~- 2~Q~3~
while it is running. The blender is then run for a total of 5iX minutes af~cr the solution addition.
The granulate ls discharged from the mixer and dried.
The G-10 granulate may be used to prepare an effervescent aspirin tahlet formulation.
Formula ET-187 mg/tab Ingredient Wt.
325 Aspirin, U.S.P. 162.5 Gm 1000 Citric Acid, Anhydrous Powder 500.0 Gm 102160 G-10 1080~0 ~m 3485 1742.5 Gm The G-10 granulate was dry sized by passage through a 2B S.S. drilled screen on a Model M Fitz-patrick Comminuting Mill, operating at 2500 rpm, knives forward. Together the citric acid and aspirin are passed through a #24 S.Sc Screen, U.S. Standard~
This mixture and the G-10 granulate are loaded into a tabletop Patterson-Kelley Twin Shell Blender, and mixed for seven minutes. The final mixture is compressed into tablets of one inch diameter to a tablet hardness of 9-12 Kp.
The resulting tablets dissolve rapidly (within approximately one minute) when placed in water. The dissolved tablet solution has good esthetic properties;
the aspirin crystals on the surface are easily dispersed into the solution by swirling, without leaving an unsightly scum ring on the sides of the glass, and the solution has a prolonged residual effervescence.
MS #1582 2~3~
Example 11 Aspirin containing effervescent tablets made with sodium bicarbonate granulates prepared with different aqueous granulating solutions for comparison.
Aqueous solutions of sodium citrate ~ET-179, Example 2)~ potassium citrate (ET-187, Example 10) and dibasic potassium fumarate (ET-339, Example 15) were compared with a similar formulation, made with heat treated sodium bicarbonate, as a control. The tablets were packaged into foil pouches cont~ining two tablets each of the respective formulations, and were tested for stability after 1 week storage at 40~C. Formulations ET-179, ET-187 and ET-339 were used as disclosed and are nonoptimized laboratory formulations. The control is a commercial, optimized product. The tablets were tested for aspirin decomposition, which was followed by the genera~ion of sodium salicylate, and for carbon dioxide genera-tion, which was followed by measurement of the physical expansion of the pouch packages. The following results were obtained:
1 Week 40~C
Sodium Salicylate Pouch Expansion Formulation mg/tab mm/pouch 25 ET-179 6.35 12.7 ET-187 5.35 3-7 ET-339 5.42 1.7 Control 5.50 0.9 MS ~1582 It can be seen from these data that ET-179, ET-187 and ET--339 are approximately equivalent to the control formulation in the matter of sodium salicylate generation as an indicator of aspirin decomposition, but not as resistant to carbon dioxide liberation from the formulations as is the control formulation.
However, all three formulations were within acceptable limits, especially for nonoptimized formulations, and were much easier to manufacture since normal wet granulation techniques could be used and special handling was not re~uired.
Example 12 - Preparation of a trisodium citrate granulate of a mixture of acetaminophen and calcium carbonate, G-1.
Two particularly troublesome compounds to granulate are acetaminophen and calcium carbonate.
Granulating Solution % w/w Ingredient Wt.
40.0 Sodium Citra~e, Dihydrate 600 Gm 20 60.0 D.I. Water _ Gm 100.0 1500 Gm MS #1582 3i~
Granulate, G-1 % w/w Ingredient Wt.
42.0 Acetaminophen, U.S.P.1772.5 Gm 49.0 Precipitated Calcium Carbonate, 2072.5 Gm U.S.P.
9.0 Sodium Citrate 380.0 Gm 100.0 4225.0 Gm The granulate, G-1, was prepared using the general procedure described previously and used to prepare a swallow tahlet.
Formula T-48 mg/tab Ingredient Wt.
782.82 G-1 626.26 Gm 31.79 Sodium Starch Glycolate, N.F. 25.43 Gm (Explotab) 0.10 Docusate: Sodium Benzoate (85:15) 0.08 Gm 4.00 Magnesium Stearate, N.F.3.20 Gm 10.00 Crospovidone, N.F. (Polyplasdone 8.00 Gm XL) 2048.29 Powdered Cellulose, N.F. (Keycel 38.63 Gm BH65) 9.00 Colloidal Silicon Dioxide, N.F. 7.20 Gm (Syloid 244FP) 886.00 708.80 Gm MS #1582 32~
The G l granulate was dry sized by passage tnrough a 0.033 inch opening, drilled S.S. screen at 3550 rpm, on a Model JT Homoloid Machine from the W.
J. Fitzpatrick Co. All ingredients except the magnesium stearate were passed through a ~24 U.S.
Standard S.S. screen two times, and then mixed in a two quart capacity V-Blender for five minutes. The magnesium stearate was delumped by spatulation and then added to the V-Blender, and the whole composition was mixed for three minutes. The composition was compressed into tablets using 0~300" x 0.700" x 0.050" (cup depth) capsule shaped tooling on a Colton 216 tablet press.
The resulting tablets had a cross sectional breaking strength of 4.6 Kp, and showed U.S.P.
dissolution test results of 94~0% at 30 minutes for acetaminophen and 99.9% at 30 minutes for calcium.
Example 13 - Preparation of a dipotassium fumarate granulate of potassium bicarhonate, G-83.
Granulating Solution O w/w Ingredient Wt.
19.2 Potassium Fumarate, Dibasic 1000 Gm 80.8 D.I. Water 4200 Gm 100.0 5200 Gm MS #1582 30~
This solu~ion is made by reacting fumaric acid and potassium bicarbonate as follows:
Ingredi.ent Wt.
Fumaric Acid, N.F.601 Gm Potassium Bicarbonate, U.S.P. 1036 Gm D.I. Water 4014 Gm The potassium bicarbonate was dissolved in the water, the fumaric acid added slowly with mixing while effervescence of the solution proceeds. The solution is warmed gently to about 44~C before it is used.
Granulate G-83 % w/w Ingredient Wt.
97.4 Potassium Bicarbonate, U.S.P. 5000 Gm 2.6 Potassium Fumarate, Dibasic 135 Gm 100.0 5135 Gm The G-83 granulate was prepared as described in the general procedure outlined previously.
MS #1582 2~93,~
Example 14 - Prcparation of a potassium sodium tartrate granulate of potassium bicarbonate, G-85.
Granulating Solution % w/w Ingredicnt Wt.
40.0 Potassium Sodium Tartrate, U.S.P. 500 Gm 60.0 D~I. Water 750 Gm 100.0 1250 Gm - Granulate, G-85 % w/w Ingredient Wt.
94.7 Potassium Bicarbonate, U.S.P. 5000 Gm 5.3 Potassium Sodium Tartrate, U.S.P. 280 Gm 100.0 5280 Gm The G-85 granulate was prepared as described in the general procedure outlined previously.
Tes~ of dry state reactivity of micronized fumaric acid with dipotassium fumarate granulate of potassium bicarbonate, ~-83, and with potassium sodium tartrate granulate of potassium bicarbonate, G-85.
Testing was conducted according to Example 12.
There was no perceptible reaction of G-83 or G-85 with micronized fumaric acid over 45 hours.
MS #1582 2~ i3~
Example 15 - Preparation of a dipotassium fumarate granulate of sodium bicarbonate, G-84.
The granulating solution of dipotassium Eumarate described in Example 13 was used to prepare granulate G-84. The granulate was prepared as described in the general procedure outline previously.
Granulate G-84 % w/w Ingredient Wt.
97.75 Sodium Bicaxbonate, U.S.P.*5000 Gm 102.25 Potassium Fumarate, Dibasic115 Gm 100.00 5115 Gm The G-84 granulate was used to prepare an effervescent aspirin tablet formulation.
Formula ET-339 15 mg/tab Ingredient Wt.
1983 G-84 594.9 1000 Citric Acid, Anhydrous Powder 300.0 324 Aspirin, U.S.P. 97.2 3307 992.1 The procedure used to test the tablets has been outlined in Example 10. The results were generally the same as those shown in Example 10. A comparison of effervescent tablets made with this method is shown in Example 11.
MS #1582 3 ~ ~
It should be understood that many modifications and variations can be made i.n the proportions and components used hercin without departing from the spirit and scope of the invention, which is solely defined by the claims.
MS #1582
Claims (8)
1. A method of preparing a granulate of a finely divided solid material, comprising the steps of:
a. mixing an effective amount of an aqueous granulating solution of composed of a sodium, potassium or mixed sodium potassium salt of a solid edible organic acid, the acid chosen from the group consisting of citric, fumaric, tartaric or malic acid with a finely divided solid material requiring granulation;
b. granulating the mixture, and c. drying the granulated mixture.
a. mixing an effective amount of an aqueous granulating solution of composed of a sodium, potassium or mixed sodium potassium salt of a solid edible organic acid, the acid chosen from the group consisting of citric, fumaric, tartaric or malic acid with a finely divided solid material requiring granulation;
b. granulating the mixture, and c. drying the granulated mixture.
2. The method of claim 1 wherein the granulating solution is prepared by dissolving trisodium citrate with water.
3. The use of the granulate prepared by the method of claim 1 to prepare a swallow or effervescent tablet.
4. A method of preparing a granulate of a finely divided solid material, comprising the steps of:
a. preparing an aqueous granulating solution by dissolving a sodium, potassium or mixed sodium potassium salt of a solid edible organic acid, the acid chosen from the group consisting of citric, fumaric, tartaric or malic acid; and potassium or sodium bicarbonate;
b. mixing an effective amount of the aqueous granulating solution with a finely divided solid material requiring granulation;
c. granulating and drying the mixture.
a. preparing an aqueous granulating solution by dissolving a sodium, potassium or mixed sodium potassium salt of a solid edible organic acid, the acid chosen from the group consisting of citric, fumaric, tartaric or malic acid; and potassium or sodium bicarbonate;
b. mixing an effective amount of the aqueous granulating solution with a finely divided solid material requiring granulation;
c. granulating and drying the mixture.
5. The method of claim 4 wherein the granulating solution is prepared by dissolving an effective amount of trisodium citrate and an effective amount of potassium bicarbonate in water.
6. A method of granulating a finely divided solid material, comprising the steps of:
a. preparing an aqueous granulating solution by dissolving an alkali metal salt chosen from the group consisting of trisodium citrate, tri potassium citrate, dipotassium fumarate or sodium potassium tartrate in water;
b. mixing an effective amount of the aqueous granulating solution with a finely divided solid material requiring granulation, the solid material chosen from the group consisting of potassium bicarbonate, acetaminophen, calcium carbonate, sodium bicarbonate, ketoprofen or a combination thereof; and c. granulating and drying the mixture.
a. preparing an aqueous granulating solution by dissolving an alkali metal salt chosen from the group consisting of trisodium citrate, tri potassium citrate, dipotassium fumarate or sodium potassium tartrate in water;
b. mixing an effective amount of the aqueous granulating solution with a finely divided solid material requiring granulation, the solid material chosen from the group consisting of potassium bicarbonate, acetaminophen, calcium carbonate, sodium bicarbonate, ketoprofen or a combination thereof; and c. granulating and drying the mixture.
7. A granulation mixture composed of:
a. an effective amount of an aqueous solution of an alkali metal salt chosen from the group consisting of trisodium citrate, tripotassium citrate, dipotassium fumarate or sodium potassium tartrate and a bicarbonate chosen from sodium or potassium bicarbonate; and b. a finely divided solid chosen from the group consisting of potassium bicarbonate, acetaminophen, calcium carbonate, sodium bicarbonate, ketoprofen or a combination thereof.
a. an effective amount of an aqueous solution of an alkali metal salt chosen from the group consisting of trisodium citrate, tripotassium citrate, dipotassium fumarate or sodium potassium tartrate and a bicarbonate chosen from sodium or potassium bicarbonate; and b. a finely divided solid chosen from the group consisting of potassium bicarbonate, acetaminophen, calcium carbonate, sodium bicarbonate, ketoprofen or a combination thereof.
8. The use of the granulation mixture of claim 6 to prepare an effervescent tablet formulation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34906089A | 1989-05-09 | 1989-05-09 | |
| US349,060 | 1989-05-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2009326A1 CA2009326A1 (en) | 1990-11-09 |
| CA2009326C true CA2009326C (en) | 1998-01-27 |
Family
ID=23370752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002009326A Expired - Fee Related CA2009326C (en) | 1989-05-09 | 1990-02-05 | Aqueous granulation solution and a method of tablet granulation |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0396972B2 (en) |
| JP (1) | JP2951686B2 (en) |
| CA (1) | CA2009326C (en) |
| DE (1) | DE69010563T3 (en) |
| ES (1) | ES2056289T5 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ239802A (en) * | 1990-09-21 | 1993-09-27 | Merrell Dow Pharma | A superior tasting pharmaceutical composition having porous particles produced through in situ gas generation and a process for its production |
| CA2061520C (en) * | 1991-03-27 | 2003-04-22 | Lawrence J. Daher | Delivery system for enhanced onset and increased potency |
| FR2700669B1 (en) * | 1993-01-22 | 1995-04-14 | Tassoni Jean Pierre | Effervescent composition for the preparation of carbonated drinks. |
| GB9316580D0 (en) * | 1993-08-10 | 1993-09-29 | Smithkline Beecham Plc | Pharmaceutical composition |
| DE4412954A1 (en) * | 1994-04-14 | 1995-10-19 | Linde Ag | Method of operating a refrigeration system |
| JP3493866B2 (en) * | 1995-12-27 | 2004-02-03 | ライオン株式会社 | Foamable oral composition |
| ATE241957T1 (en) * | 1997-09-16 | 2003-06-15 | Gergely Dr & Co | EFFORTABLE PREPARATION AND METHOD FOR PRODUCING IT |
| ATE392885T1 (en) * | 2000-02-28 | 2008-05-15 | Pharmakodex Ltd | ADMINISTRATION SYSTEMS FOR ORAL MEDICATIONS |
| US7198653B2 (en) | 2003-07-31 | 2007-04-03 | Delavau Llc | Calcium carbonate granulation |
| US7351853B2 (en) | 2006-01-23 | 2008-04-01 | Albion Advanced Nutrition | Method of manufacturing a granular mineral composition |
| GB0607085D0 (en) * | 2006-04-07 | 2006-05-17 | Smithkline Beecham Corp | Novel compositions |
| US9138414B1 (en) | 2006-09-15 | 2015-09-22 | Delavau Llc | Calcium supplement having enhanced absorption |
| WO2013022410A2 (en) * | 2011-08-08 | 2013-02-14 | Mahmut Bilgic | Production method for effervescent formulations comprising dexketoprofen |
| EP2809311A1 (en) * | 2012-01-31 | 2014-12-10 | Mahmut Bilgic | Effervescent tablet formulations comprising the combination of voglibose and metformin |
| WO2013115746A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | A production method for (effervescent) pharmaceutical compositions comprising an alpha - glucosidase inhibitor (miglitol) and metformin |
| WO2013115745A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | A process for production of pharmaceutical (effervescent) composition comprising alpha - glucosidase inhibitor (e.g. vogliobose and metformin) |
| EP3176222A1 (en) * | 2015-12-01 | 2017-06-07 | Omya International AG | Method for the production of granules comprising surface-reacted calcium carbonate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB882567A (en) * | 1959-05-30 | 1961-11-15 | Smith & Nephew | Improvements in or relating to the stabilization of dichloralphenazone |
| GB1475861A (en) * | 1976-03-19 | 1977-06-10 | Warner Lambert Co | Pharmaceutical composition |
| AU1087883A (en) * | 1982-02-02 | 1983-08-11 | Bayer Aktiengesellschaft | Water dispersible, soluble granules |
| CA1209040A (en) * | 1982-12-21 | 1986-08-05 | Jean Bru | Manufacture of effervescent granules or tablets |
-
1990
- 1990-02-05 CA CA002009326A patent/CA2009326C/en not_active Expired - Fee Related
- 1990-04-26 DE DE1990610563 patent/DE69010563T3/en not_active Expired - Fee Related
- 1990-04-26 EP EP19900107972 patent/EP0396972B2/en not_active Expired - Lifetime
- 1990-04-26 ES ES90107972T patent/ES2056289T5/en not_active Expired - Lifetime
- 1990-05-07 JP JP2115940A patent/JP2951686B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69010563T2 (en) | 1994-11-03 |
| EP0396972A3 (en) | 1992-09-23 |
| DE69010563D1 (en) | 1994-08-18 |
| EP0396972B2 (en) | 1998-06-24 |
| EP0396972A2 (en) | 1990-11-14 |
| EP0396972B1 (en) | 1994-07-13 |
| JPH02295918A (en) | 1990-12-06 |
| JP2951686B2 (en) | 1999-09-20 |
| CA2009326A1 (en) | 1990-11-09 |
| ES2056289T3 (en) | 1994-10-01 |
| DE69010563T3 (en) | 1998-10-15 |
| ES2056289T5 (en) | 1998-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5348745A (en) | Aqueous granulation solution and a method of tablet granulation | |
| CA2009326C (en) | Aqueous granulation solution and a method of tablet granulation | |
| US4806358A (en) | Therapeutic compositions | |
| CA1299583C (en) | Effervescent couples, histamine h -antagonist effervescent compositions containing them and their preparation | |
| US5656293A (en) | Delivery system for enhanced onset and increased potency | |
| US6497905B1 (en) | Aqueous solubility pharmaceutical formulations | |
| JP2735903B2 (en) | Ibuprofen boiling formulation | |
| US4093710A (en) | Rapid dissolving effervescent granules | |
| JP2608183B2 (en) | Pimobendan oral dosage form | |
| US5690959A (en) | Pharmaceutical thermal infusion process | |
| US20070190161A1 (en) | Solid formulation for dialysis and process for producing the same | |
| US4255413A (en) | Gelatin capsule dosage unit containing triamterene | |
| WO1996023499A1 (en) | Extended-release solid oral dosage forms of drugs having low solubility in water | |
| WO2001024801A1 (en) | Pharmaceutical formulations containing poorly soluble drug substances | |
| SK283249B6 (en) | Tablet, manufacturable by direct tableting, containing an active substance 4-amino-1-hydroxybutylidene-1,1-biphosphonic acid and process for its preparation | |
| JP3266261B2 (en) | Tyridine dihydrogen orthophosphate, a method for producing the same and a drug containing the same | |
| US5827537A (en) | Pharmaceutical thermal infusion process | |
| ES2333332T3 (en) | NON-EFFECTIVE FORM OF SODIUM NAPROXENE THAT INCLUDES BETWEEN OTHER SODIUM HYDROGENOCARBONATE. | |
| HU191542B (en) | Process for production of pastiles containing dipyridamel independent from ph with regulated output of the active substance | |
| JP2002531577A (en) | Pharmaceutical composition containing quinapril magnesium | |
| JP2841857B2 (en) | Long-term stable oral pharmaceutical preparation | |
| MXPA01009542A (en) | Improved aqueous solubility pharmaceutical formulations | |
| JPH0129169B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed | ||
| MKLA | Lapsed |
Effective date: 20010205 |